ClinicalTrials.gg
CompletedNCT00935506Updated Feb 23, 2011

Ex Vivo Human Thrombosis Chamber Study

A Phase 1 interventional study of Clopidogrel and Aspirin in Cardiovascular Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-02-23.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Purpose of study is to evaluate a thrombosis chamber model

02

Conditions studied

  • Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's enrollment of 15 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Subjects
  • 18-30 kg/m²
  • Male ages 18-45

Exclusion criteria

Exclusion Criteria:

  • Significant acute or chronic illness
  • History of abnormal bleeding or coagulation disorder, intracranial hemorrhage, or a family history of abnormal bleeding or coagulation disorder in a first degree relative under 50 years of age
  • Easy bruising
  • Smoking within 3 months prior to Day 1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Clopidogrel + Aspirin

    Drug: Clopidogrel · Drug: Aspirin

Interventions

  • Tablets, Oral, 75 mg, Once daily, 8 days

    Also known as: Plavix

  • Tablets, Oral, 325 mg, Once daily, 8 days

06

What researchers measure

Primary outcomes

  1. Evaluate ex vivo thrombosis chamber model by assessing the effect of anti-platelet agents on thrombus formation

    Time frame: Period 2, Day 8

Secondary outcomes

  1. Assess variability of thrombosis chamber measurements

    Time frame: Period 1 and Period 2

  2. Assess relationship between platelet aggregation and thrombus formation

    Time frame: Period 1 and Period 2

  3. Safety and tolerability of multiple doses clopidogrel and aspirin

    Time frame: From Day 1 through Study Discharge

07

Study locations

1 site
  • Mds Pharma Services
    Neptune, New Jersey 07753, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2009
First posted
Jul 9, 2009
Start
Jul 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Feb 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00935506
First posted
Jul 9, 2009
Start date
Jul 2009
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Feb 23, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clopidogrel · Aspirin

Start the discussion